glp 1 agonists with cardiovascular benefit GLP-1 in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies glp 1 agonist risks GLP-1
Description
Out-of-pocket costs for GLP-1 therapies can be substantial, often exceeding what many individuals can sustain over time
Novos 2022 investor report saw an 84% growth in obesity-related sales between 2021 and 2022
the max is 15 mg)
Int J Ophthalmol
GLP-1 receptor agonists have a protective effect on the kidneys, reducing the risk of macroalbuminuria, but perhaps do not help preserve the glomerular filtration rate as much as sodium-glucose transporter-2 inhibitors
